-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationTom Lee
Despite Bojian’s best efforts, Tecfidera generic drugs seem to continue to be sold on the market
According to court documents filed on Tuesday, the U.
This case originated from a long-standing patent dispute between Bojian and Viatris, whose predecessor was Mylan
At that time, Bojian filed an appeal
According to Tuesday’s ruling, Bo Jianfang can still apply for a retrial and may appeal to the Supreme Court
Abrahams added that due to the bad news from Tecfidera and Bojian’s struggling in several other business areas, the company’s stock price may be “close to the bottom”
However, the fact is that the drug has continued to face safety disputes and payment barriers after it was approved by the US FDA
However, the company did not completely give up its efforts in the multiple sclerosis market.
Reference source: Biogen takes another blow as appeal for Tecfidera patent revival falls short